News from optimer pharmaceuticals, inc

Aug 01, 2013, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Reports Second Quarter 2013 Financial Results

 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the second quarter ended June 30, 2013....

Jul 25, 2013, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2013 Financial Results

 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) (the "Company" or "Optimer") today announced it will report second quarter 2013 financial...

May 13, 2013, 16:04 ET

Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer

 Optimer Pharmaceuticals (NASDAQ: OPTR) (the "Company" or "Optimer") today announced the appointment of Mr. Eric Sirota as Chief...

May 09, 2013, 16:02 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Reports First Quarter 2013 Financial Results

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the first quarter ended March 31, 2013....

May 02, 2013, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) (the "Company" or "Optimer") today announced it will report first quarter 2013 financial results...

Apr 26, 2013, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

DIFICID® (fidaxomicin) Tablets Approved in Australia

 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Therapeutic Goods Administration, the Australian regulatory body for...

Mar 15, 2013, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on March 14, 2013 the Compensation, Nominating, and Corporate Governance...

Feb 28, 2013, 16:06 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results

 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the fourth quarter and fiscal year...

Feb 27, 2013, 08:15 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on February 26, 2013 the Inducement Award Sub-Committee of the Compensation,...

Feb 27, 2013, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals' Board of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer

 The Board of Directors of Optimer Pharmaceuticals (NASDAQ: OPTR) (the "Company" or "Optimer") today announced the appointment of its...

Feb 14, 2013, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

New Analysis Shows Age has a Significant Effect on Outcomes in Patients Being Treated for Clostridium difficile Infection (CDI)

 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the February 2013 Journal of the American Geriatrics Society published...

Feb 07, 2013, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results

 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced it will report fourth quarter and fiscal year 2012 financial results after the...

Feb 07, 2013, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals to Present at Leerink Swann Global Healthcare Conference

 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the Leerink Swann Global Healthcare Conference...

Feb 01, 2013, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on January 31, 2013 the Inducement Award Sub-Committee of the Compensation,...

Jan 07, 2013, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals Reports Preliminary 2012 Gross Product Sales of $74.4 Million

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today provided an update on 2012 sales for DIFICID (fidaxomicin) tablets, an antibacterial drug...

Dec 24, 2012, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on December 21, 2012 the Inducement Grant Sub-committee of the Compensation,...

Dec 20, 2012, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 31st Annual J.P. Morgan Healthcare conference on...

Dec 05, 2012, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference

 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 23rd Annual Oppenheimer Healthcare...

Dec 03, 2012, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals and AstraZeneca Collaborate to Commercialize Fidaxomicin for Clostridium Difficile Infection in Latin America

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today the execution of an exclusive agreement with AstraZeneca to commercialize fidaxomicin...

Nov 07, 2012, 08:00 ET
Optimer Pharmaceuticals, Inc., logo. (PRNewsFoto/Optimer Pharmaceuticals, Inc.)

Optimer Pharmaceuticals to Present at November 2012 Investor Conferences

 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the below listed investor conferences in...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
ReportBuyer
Investor-Edge